# Alkermes plc (ALKS) Stock Analysis: Strong Buy Ratings and a Promising 32% Upside Potential

- Link: https://www.directorstalkinterviews.com/alkermes-plc-alks-stock-analysis-strong-buy-ratings-and-a-promising-32-upside-potential/4121240084
- Published: 2026-02-16T11:32:09+00:00
- Author: Madison Wilson

Alkermes plc (NASDAQ: ALKS), a notable player in the biopharmaceutical industry,
is attracting significant attention from investors due to its promising growth potential
and strong market positioning. With a market capitalization of $5.48 billion, Alkermes
is strategically headquartered in Dublin, Ireland, and operates within the Healthcare
sector, specifically focusing on specialty and generic drug manufacturing.

The company has carved a niche for itself by addressing unmet medical needs through
its portfolio of proprietary commercial products. These include ARISTADA and ARISTADA
INITIO, both used for treating schizophrenia, as well as VIVITROL for alcohol dependence
and opioid prevention, and LYBALVI for schizophrenia and bipolar I disorder. Alkermes
also leverages proprietary technology platforms to collaborate with pharmaceutical
giants like Janssen Pharmaceutica, further solidifying its market presence.

Currently, Alkermes is trading at $33.16, with a 52-week range of $26.13 to $35.90.
While the stock’s price remained unchanged in the latest session, the forward-looking
metrics paint a brighter picture. The forward P/E ratio stands at 15.35, suggesting
potential value compared to its peers. The company’s revenue growth of 4.20% and
a robust return on equity of 22.35% further underscore its financial health and 
operational efficiency.

Despite the absence of a trailing P/E and a PEG ratio, Alkermes’ performance metrics
highlight its profitability. With an EPS of 2.01 and a free cash flow of over $342
million, the company is well-positioned to reinvest in growth opportunities and 
continue its innovative endeavors.

Alkermes does not currently offer a dividend, as reflected by its payout ratio of
0.00%. This retention of earnings might be a strategic decision to fuel future expansion
and R&D initiatives, which could lead to higher stock valuations in the long run.

Analyst sentiment towards Alkermes is overwhelmingly positive. The stock has garnered
14 buy ratings, 3 hold ratings, and no sell ratings. With an average target price
of $43.81, analysts project a potential upside of 32.12%, positioning Alkermes as
a compelling investment option for growth-oriented investors. The target price range
varies from $30.00 to a high of $58.00, indicating a broad consensus on its upward
trajectory.

From a technical perspective, Alkermes trades above both its 50-day moving average
of $30.85 and its 200-day moving average of $29.84, signaling a positive trend. 
The Relative Strength Index (RSI) at 44.50 suggests the stock is neither overbought
nor oversold, while the MACD and signal line values indicate a stable momentum.

Alkermes’ strategic focus on neurological disorders and its commitment to innovation,
combined with solid financial metrics and favorable analyst ratings, make it a noteworthy
consideration for investors seeking exposure in the biopharmaceutical sector. As
the company continues to expand its portfolio and leverage strategic collaborations,
Alkermes is poised to deliver substantial returns for its shareholders.

Share on: